US Bancorp DE Has $287,000 Position in Prestige Consumer Healthcare Inc. (NYSE:PBH)

US Bancorp DE increased its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 20.3% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,978 shares of the company’s stock after purchasing an additional 672 shares during the period. US Bancorp DE’s holdings in Prestige Consumer Healthcare were worth $287,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System raised its position in Prestige Consumer Healthcare by 77.4% in the first quarter. State Board of Administration of Florida Retirement System now owns 25,221 shares of the company’s stock worth $1,830,000 after purchasing an additional 11,000 shares in the last quarter. Lombard Odier Asset Management USA Corp bought a new stake in Prestige Consumer Healthcare during the second quarter worth about $550,000. CANADA LIFE ASSURANCE Co grew its stake in Prestige Consumer Healthcare by 19.4% during the first quarter. CANADA LIFE ASSURANCE Co now owns 47,575 shares of the company’s stock worth $3,453,000 after buying an additional 7,715 shares during the last quarter. Sequoia Financial Advisors LLC grew its stake in Prestige Consumer Healthcare by 12.9% during the third quarter. Sequoia Financial Advisors LLC now owns 9,824 shares of the company’s stock worth $708,000 after buying an additional 1,120 shares during the last quarter. Finally, Atria Investments Inc bought a new stake in Prestige Consumer Healthcare during the first quarter worth about $1,246,000. Institutional investors and hedge funds own 99.95% of the company’s stock.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $76.00 price objective (up from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. DA Davidson reaffirmed a “buy” rating and set a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Prestige Consumer Healthcare has a consensus rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Price Performance

PBH opened at $82.32 on Thursday. Prestige Consumer Healthcare Inc. has a one year low of $56.61 and a one year high of $83.13. The company has a debt-to-equity ratio of 0.61, a current ratio of 3.56 and a quick ratio of 2.10. The company’s 50 day simple moving average is $72.84 and its 200-day simple moving average is $70.00. The stock has a market capitalization of $4.07 billion, a P/E ratio of 20.08, a price-to-earnings-growth ratio of 2.30 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, November 7th. The company reported $1.09 EPS for the quarter, meeting the consensus estimate of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same period in the prior year, the firm earned $1.07 earnings per share. Prestige Consumer Healthcare’s revenue was down .9% compared to the same quarter last year. Sell-side analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current fiscal year.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.